About the journal
Clinical Breast Cancer is a journal published by Elsevier BV in United States. It is listed in MEDLINE according to the sources read. Declared publication charge: 3,290 USD. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- Elsevier BV
- ISSN
- 1526-8209 · 1938-0666
- Country
- United States
- Access
- Not open access / not declared
- Declared publication charge
- 3,290 USD
- Declared peer-review model
- peer_review
- Official website
- https://www.journals.elsevier.com/clinical-breast-cancer
Index listings
- MEDLINE · 2000-01-01
- Indexing
- MEDLINE
- APC
- 3,290 USD
- Declared review time (DOAJ)
- —
- Actual review time (measured)
- 75 days received→accepted — computed from PubMed (n=100)
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Works in OpenAlex
3335
Last recorded publication year
2026
h-index
98
i10-index
1591
From OpenAlex open data (CC0).
Editorial & policy4
- Observed digital preservation (Keepers registry)— snapshot 2026-10-05
- CLOCKSSPortico
- Norwegian register (HK-dir)— 2026
- Level 1 — approved scholarly channel
- Open references deposited at Crossref
- 95%
- ORCID iDs in current deposits
- 72%
- Deposits licence metadata at Crossref
- ✓
Identity & continuity3
- Alternate titles
- Clin Breast CancerBreast cancer
- Source type
- journal
- NLM unique ID (PubMed)
- 100898731
Classification(no data)
No data available to the platform for this group
No platform data for: Classification — absence is not a judgment about the journal.
Subject areas
- Breast Cancer Treatment Studies
- Breast Cancer Treatment Studies
- Breast Lesions and Carcinomas
- Breast Lesions and Carcinomas
- HER2/EGFR in Cancer Research
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Treatment and Pharmacology
Show all subjects (50)
- Breast Implant and Reconstruction
- Breast Implant and Reconstruction
- Advanced Breast Cancer Therapies
- Advanced Breast Cancer Therapies
- Estrogen and related hormone effects
- Estrogen and related hormone effects
- Cancer Risks and Factors
- Global Cancer Incidence and Screening
- Cancer Risks and Factors
- Global Cancer Incidence and Screening
- BRCA gene mutations in cancer
- BRCA gene mutations in cancer
- Diverse Scientific and Economic Studies
- Diverse Scientific and Economic Studies
- Cancer survivorship and care
- Cancer survivorship and care
- MRI in cancer diagnosis
- Male Breast Health Studies
- Male Breast Health Studies
- MRI in cancer diagnosis
- Lymphatic System and Diseases
- Lymphatic System and Diseases
- Reconstructive Surgery and Microvascular Techniques
- Reconstructive Surgery and Microvascular Techniques
- Human auditory perception and evaluation
- Human auditory perception and evaluation
- Medical Imaging Techniques and Applications
- Medical Imaging Techniques and Applications
- Educational Robotics and Engineering
- Educational Robotics and Engineering
- Big Data and Digital Economy
- Ferroelectric and Negative Capacitance Devices
- Big Data and Digital Economy
- Ferroelectric and Negative Capacitance Devices
- Monoclonal and Polyclonal Antibodies Research
- Monoclonal and Polyclonal Antibodies Research
- Digital Radiography and Breast Imaging
- Digital Radiography and Breast Imaging
- Cancer Cells and Metastasis
- Cancer Cells and Metastasis
- Cancer and Skin Lesions
- Cancer and Skin Lesions
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
The journal's record in other sources:Web of Science MJLDOAJ